Humacyte Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-110.78	-11.97	-26.48	-66.52	-85.42
Depreciation & Amortization	7.77	8.26	8.28	8.43	6.81
Share-Based Compensation	6.83	6.18	10.15	4.69	4.46
Other Operating Activities	22.87	-73.6	-73.14	-2.17	2.37
Operating Cash Flow	-73.31	-71.13	-81.19	-55.57	-71.79
Capital Expenditures	-2.28	-1.05	-0.22	-0.27	-8.13
Change in Investments	2.11	5.89	-8	0	0
Investing Cash Flow	-0.17	4.85	-8.22	-0.27	-8.13
Share Issuance / Repurchase	0.57	0.54	243	0.3	1.22
Debt Issued / Paid	4.17	-1.98	27.93	1.75	-1.29
Other Financing Activities	-0.23	-	-3.95	-	-
Financing Cash Flow	4.51	-1.45	266.98	2.05	-0.07
Net Cash Flow	-68.97	-67.73	177.57	-53.78	-79.99
Free Cash Flow	-75.59	-72.18	-81.41	-55.84	-79.91
Free Cash Flow Margin	-	-4611.95%	-6445.76%	-3744.87%	-1291.61%
Free Cash Flow Per Share	-0.73	-0.70	-2.04	-9.68	-3.97

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).